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13.08.003Abstract Induced pluripotent stem (iPS) cells can be generated by forced expression of four
pluripotency factors in somatic cells. This has received much attention in recent years since it
may offer us a promising donor cell source for cell transplantation therapy. There has been great
progress in iPS cell research in the past few years. However, several issues need to be further
addressed in the near future before the clinical application of iPS cells, like the immunogenicity
of iPS cells, the variability of differentiation potential and most importantly tumor formation of
the iPS derivative cells. Here, we review recent progress in research into the pluripotency of
iPS cells.Introduction
Induced pluripotent stem (iPS) cells can be derived from
mouse somatic cells via the ectopic expression of four deﬁned
factors, Oct4, Sox2, Klf4 and c-Myc (also known as Yama-
naka factors) [1]. The mouse iPS cells express pluripotency
markers and both X chromosomes are reactivated, allowing
differentiation into various cell types of three germ layers when
injected into a blastocyst. iPS technology makes reprogram-
ming much easier [2,3] in comparison to early reprogramming
methods such as somatic cell nuclear transfer (SCNT) [4,5], iPS
technology also circumvents the ethical problems arising from
the use of human oocytes. In addition, the generation of).
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[6,7]. However, there are currently several limitations in apply-
ing iPS cells clinically. Efﬁciency of converting somatic cells to
iPS cells is still very low. In particular, only approximately
0.1% to 1% of somatic cells experience changes at the tran-
scriptional level and ﬁnally become pluripotent stem cells when
non-integration approaches are used [8]. Moreover, compared
to embryonic stem (ES) cells, the developmental potential and
differentiation capacity of iPS cells is signiﬁcantly reduced and
there is increased variability among all iPS cell lines [9]. In
mice, only small proportions of these cells are fully repro-
grammed based on the most stringent tetraploid complementa-
tion assay for evaluating pluripotency [10–13]. Therefore, it is
necessary to establish a strict molecular standard system to dis-
tinguish fully reprogrammed iPS cells from those partially
reprogrammed, as we currently lack suitable in vivo pluripoten-
cy tests for human iPS cells.
In this review, we mainly focus on recent progress on ro-
dent, non-human primate and human iPS cells, and point
out some key questions which need to be addressed in the near
future, such as the pluripotency level of human iPS cells andcademy of Sciences and Genetics Society of China. Production and hosting
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level of human iPS cells.
Generation of non-integration iPS cells
Takahashi and Yamanaka reprogrammed mouse embryonic
ﬁbroblasts by the ectopic expression of four reprogramming
factors using retroviral vectors, and ﬁnally produced iPS cells
which resemble ES cells [1]. This original iPS reprogramming
approach used viral vectors, including retrovirus and lentivirus
which possess high reprogramming efﬁciency [14,15]. The gen-
ome may be mutated by integrating other gene sequences, thus
raising concerns on the safety issue. In addition, the insertion
of oncogenes, like c-Myc, increases the risk of tumor forma-
tion [16,17]. Subsequently, several modiﬁed methods were used
to obtain much safer iPS cells, for instance, piggyBac transpo-
son [18], adenovirus [19], sendai virus [20], plasmid [21], epi-
somal vectors [22] and minicircle vectors [23]. However, the
reprogramming efﬁciency is signiﬁcantly decreased and it takes
longer to reactivate the key pluripotency markers to achieve
full reprogramming. Therefore, efﬁcient generation of non-
integrated iPS cells by new approaches may promote their clin-
ical application.
Recent studies have described several reprogramming
methods using proteins, RNAs and small-molecule com-
pounds to derive safe iPS cells [24–26]. Zhou et al. obtained
iPS cells induced by recombination of the proteins of the four
Yamanaka factors obtained by fusing the C-terminus of the
proteins with poly-arginine (11R) [24]. A recent study reported
that mouse and human iPS cells can be efﬁciently generated by
miRNA mediated reprogramming [25]. Miyoshi et al. [26] suc-
cessfully generated iPS cells by direct transfection of human
somatic cells using mature miRNA. iPS cells can also be gen-
erated by synthetic RNAs, which bypass the innate response to
viruses [27]. Recently, Houet et al. [28] showed that pluripotent
stem cells can be generated from mouse somatic cells at an efﬁ-
ciency of 0.2% by using a combination of seven small-moleculeTable 1 Summary of different reprogramming methods for the genera
Viral or nonviral Type of vector Genomic integration Advantag
Viral Retrovirus Yes Stably int
high eﬃc
Lentivirus Yes Reduces
transgene
high eﬃc
Adenovirus No* Lacking v
high eﬃc
Sendai virus No** Lacking v
high eﬃc
Nonviral piggyBac transposon No*** Virus-free
Plasmid No* Virus-free
plasmid i
Episomal vector No* Virus-free
Minicircle vector No* Virus-free
Protein No Virus-free
RNA No Virus-free
Small molecule No Virus-free
Note: * Lack of genomic integration can be examined; ** lack of virus RNA
the genome.compounds. Compared to traditional viral methods, the afore-
mentioned approaches can be used to generate qualiﬁed iPS
cells (Table 1) without the risk of insertional mutagenesis.
Nonetheless, some familiar drawbacks exist, such as a longer
and less efﬁcient reprogramming process. In other words, what
we need to do next is to optimize non-integration induction
systems in order to resolve these drawbacks.
The pluripotency of mouse iPS cells
Pluripotency of mouse ES and iPS cells can be detected by a
series of testing standards. These standards include the expres-
sion of pluripotency markers, alkaline phosphatase (AP) stain-
ing, teratoma formation in vitro, the formation of diploid
chimera, and tetraploid complementation. The ﬁrst-generation
of iPS cells resemble ES cells in morphology and express some
pluripotency markers, but are not able to produce live chimeric
mice [1], indicating that the original iPS cells were not fully
reprogrammed to pluripotent stem cells. Subsequently, modi-
ﬁed protocols were used for reprogramming to create im-
proved qualiﬁed iPS cells, which resulted in the generation of
live chimeric mice with germline transmission [16,29].
Whether fully reprogrammed pluripotent stem cells have
the ability to generate iPS-mice through tetraploid comple-
mentation has been questioned for a long time until 2009,
when live pups were ﬁnally generated in two independent
research laboratories [12,13]. Since then, no matter
reprogrammed by one or three factors [30,31], using adult or
fetal cells [13,32], the iPS cells are able to generate iPS-mice,
even after genetic modiﬁcation.
However, not all mouse iPS cells are able to pass the most
rigorous tetraploid complementation assessment. Therefore it
is important to identify molecular markers which can predict
the pluripotency level of iPS cells, which will help future mech-
anistic studies. A small number of transcriptionally active
genes within the imprinted Dlk1-Dio3 gene cluster on chromo-
some 12qF1, particularly Glt2 and Rian, are aberrantlytion of iPS cells
es Disadvantages Ref
egrated into the host genome;
iency
Too risky because of their
insertional tendencies;
cause tumor formation
[1,16]
the risk of
expression;
iency
Too risky because of their
insertional tendencies
[14]
iral integration;
iency
Tend to carry the
virus genome
[19]
iral integration;
iency
Tend to carry the
virus genome
[20]
A labor-intensive process [18]
; no integration of the
nto the host genome
Lower eﬃciency; four
rounds of transfection
[21]
; a single transfection Lower eﬃciency [22]
; higher transfection eﬃciency Longer ectopic expression [23]
Lower eﬃciency [24]
; high eﬃciency Labor-intensive procedures [25–27]
Lower eﬃciency [28]
genome can be examined; *** transposon vector can be removed from
Feng C et al / Pluripotency of Induced Pluripotent Stem Cells 301silenced in most iPS cell lines. These iPS cell lines poorly con-
tribute to chimeras and fail to support the development of iPS
cell-derived embryos generated by tetraploid complementation
[33,34]. In contrast, in fully pluripotent iPS cell lines these
genes are expressed at levels comparable to those in embryonic
stem cells.
The pluripotency of human iPS cells
Human iPS cells produced via somatic cell reprogramming
have opened up another new territory for regenerative medi-
cine. Human iPS cells generated from adult human ﬁbroblasts
express hES cell-speciﬁc surface antigens, including SSEA-3,
SSEA-4, tumor-related antigen (TRA)-1–60, TRA-1–81 and
NANOG protein, while displaying high telomerase activity
and multiple differentiation potential [35–37]. In addition,
human iPS cells can differentiate into cells of all three germ
layers. However, unlike the mouse situation, there are no suit-
able in vivo testing standards for human ES/iPS cells available
that can be applied to test the in vivo functions in embryonic
development and pluripotency. As a result, the failure to dis-
tinguish pluripotent cell lines will hinder clinical application
in the future (Table 2).
The pluripotency of naı¨ve iPS cells
Pluripotency can be deﬁned as the ability of a single cell to dif-
ferentiate into all types of somatic cells in an adult organism.
Rodent pluripotent stem cells can be considered to exist in
two distinct states: naı¨ve and primed [38]. Rodent naı¨ve plurip-
otent stem cells can be derived through expansion of the innerTable 2 Pluripotency levels of ES/iPS cells vary among different spec
Cell type Species Pluripotency
markers
AP
staining
Terat
forma
ES/iPS Mouse Positive Positive Yes
ES/iPS Rat Positive Positive Yes
ES/iPS Human Positive Positive Yes
ES/iPS Rhesus monkey Positive Positive Yes
Note: n indicates that chimera assay cannot be used in human ES/iPS plur
Pluripotency
   markers
Teratoma 
formation
D
ch
Monkey iPS cells
Mouse iPS cells
Human iPS cells
Primed s
Figure 1 Comparison of pluripotency levels ofcell mass (ICM) of the blastocyst, the reprogramming of so-
matic cells, or the reversion of primed pluripotent cells. Ro-
dent primed pluripotent stem cells can be accessed through
harvesting the post-implantation epiblast or pre-implantation
blastocyst [39–41]. Naı¨ve and primed iPS cells have some com-
mon characteristics: indeﬁnite self-renewal, tri-germ layer dif-
ferentiation potential and reliance on the core transcription
factors Oct4, Sox2 and Nanog. However, naı¨ve pluripotent
stem cells are distinguished from primed cells in that they rely
mainly on leukemia inhibitory factor (LIF) signaling and
MEK/GSK3 inhibition to maintain their self-renewal, two ac-
tive X chromosomes in female cells and pluripotency to gener-
ate high-grade chimeras, even tetraploid complementation
animal [11,42–44]. Primed pluripotent stem cells, however, de-
pend on the Activin-nodal signaling pathway. They generate
chimeric mice with low efﬁciency and fail to contribute to
the germline of chimeric mice [40].
Human embryonic stem cells are derived from pre-implan-
tation blastocysts and more closely resemble mouse epiblast
stem cells in pluripotency level, when compared with rodent
counterparts [45]. In fact, several attempts to capture human
naı¨ve pluripotent stem cells have been carried out. Naı¨ve-like
female human ES cells (with two active X chromosomes) were
derived in 5% oxygen and conventional human ES culture
conditions containing bFGF [46]. NANOG-positive cells can
be harvested from human pre-implantation embryos and
maintained in vitro at physiological oxygen concentrations
when supplemented with FGF inhibitor or 2i, which is used
to stabilize naı¨ve rat ES cells. This suggests that some transient
naive cells may exist in early human embryos [47,48]. Though
we have witnessed exciting progress in the ﬁeld of naı¨ve human
pluripotent stem cells research, deﬁnitive evidence for naı¨veies
oma
tion
Diploid chimera/germline Tetraploid
complementation
Ref
Yes/Yes Yes [1,16]
Yes/Yes Unknown [47]
n n [35,45]
Unknown/Unknown Unknown [49–51]
ipotency test.
iploid 
imera
Diploid chimera
    /germline
      Tetraploid 
complementation
tate
NaÏve state
iPS cells from mouse, human and monkey
302 Genomics Proteomics Bioinformatics 11 (2013) 299–303human pluripotent stem cell state is lacking. Although repro-
gramming mouse embryonic ﬁbroblast using the four Yama-
naka factors in mouse ES culture medium yields naı¨ve
mouse iPS cells, similar endeavor in reprogramming human
embryonic ﬁbroblasts by applying naı¨ve culture condition gen-
erates human iPS cell lines that lack characteristic qualities
seen in bona ﬁde mouse ES/iPS cells [1,15]. This suggests a crit-
ical question: whether human naı¨ve-speciﬁc pluripotent stem
cells can feature characteristics seen in rodent cell lines.
Non-human primate ES cells and iPS cells share very simi-
lar characteristics with regard to pluripotency markers, gene
expression and ability to differentiate into all three germ layers
[49,50]. The chimera assay can be used to distinguish primed
and naı¨ve rodent pluripotent stem cells, which cannot be used
on human cells. Non-human primate cells may be the most
ideal substitute to test the rodent paradigm (Figure 1). Similar
to mouse primed stem cells (epiblast stem cells), a report shows
that rhesus monkey ES cells cannot produce high-grade chime-
ric embryos or blastocysts [51], although ES cells can be ob-
served in the ICM of blastocyst transiently when introduced
to four-cell stage embryos. These results suggest that non-hu-
man primate embryonic stem cells are therefore primed stem
cells. Primates, as the model animal most similar to human,
can be used for chimera arrays to screen Naı¨ve pluripotent
stem cells. Additionally, development of new methods to func-
tionally evaluate non-human pluripotent stem cells, such as by
establishing a fetal chimera array, may help to evaluate the
pluripotency level of human pluripotent stem cells in the
future.
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